The BioCentury Show

BioCentury Podcasts
  • ٤٫٦ (١٠)
  • علوم حياة
  • يتم التحديث كل أسبوعين
The BioCentury Show

Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine. Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues. The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine. Don't miss this event, every two weeks, now available as a video webcast or audio podcast.

  1. Ep. 77 - AI’s Next Leap: Foresite Labs’ Vik Bajaj on Predictive Biology

    ٨ شعبان

    Ep. 77 - AI’s Next Leap: Foresite Labs’ Vik Bajaj on Predictive Biology

    Clinical trials will be launched in the next year or two to test predictions about causal biology made by artificial intelligence models, Vik Bajaj, co-founder and CEO of Foresite Labs and managing director of Foresite Capital Management, believes. Foresite teamed up with Arch Venture Partners last year on a $1 billion venture round to fund Xaira Therapeutics, which aims to reinvent the R&D process via AI-driven protein design and biological discovery technologies. Bajaj, who serves as in...

    ٣٥ من الدقائق
  2. Ep. 76 - FDA Inflection Point: Steve Usdin on Biopharma during Trump 2.0

    ٢٤ رجب

    Ep. 76 - FDA Inflection Point: Steve Usdin on Biopharma during Trump 2.0

    All presidential transitions with a change of party come with disruption and threats as well as opportunities. But this one, in particular with regard to the implications for FDA, is different from all those Steve Usdin has been covering in his 30-year tenure as Washington editor at BioCentury. In particular, this is an inflection point for the agency that currently serves as the global gold standard for drug regulation, said Usdin on a special edition of The BioCentury Show covering the rami...

    ٣٤ من الدقائق
  3. Ep. 75 - PBMs, IRA, RFK Jr: A Conversation With Rep. Jake Auchincloss

    ١٣ رجب

    Ep. 75 - PBMs, IRA, RFK Jr: A Conversation With Rep. Jake Auchincloss

    Rep. Jake Auchincloss (D-Mass.), an influential voice in Congress on life sciences issues, gained stature last week when he was appointed to serve on the Energy & Commerce Committee, giving him a seat at the table for debates over legislation affecting FDA, CMS and NIH and a host of issues of critical importance to the biopharma industry.In an interview with Washington Editor Steve Usdin on The BioCentury Show, Auchincloss outlined his priorities for the 119th Congress, from pushing “musc...

    ٣٦ من الدقائق
  4. Ep. 74 - Chris Bardon on Biotech’s Recovery: Valuations, Obesity Drugs, and M&A

    ١٠ رجب

    Ep. 74 - Chris Bardon on Biotech’s Recovery: Valuations, Obesity Drugs, and M&A

    Specialist public investors are doing their best to hold up the sector, but biotech still has to wash out many of the lower quality companies that were funded during the boom and ended up driving the generalists away, said MPM Bioimpact's Chris Bardon on The BioCentury Show. Bardon said the market hasn’t yet found the footing that will see an opening of the IPO window and a swing of positive sentiment. But although markets aren’t yet out of the woods, she said M&A will remain robust for y...

    ٣٤ من الدقائق
  5. Ep. 73 - Resilience and the CEO’s Paradox: Aoife Brennan on Leading in Biotech

    ١٢‏/٠٦‏/١٤٤٦ هـ

    Ep. 73 - Resilience and the CEO’s Paradox: Aoife Brennan on Leading in Biotech

    Leading biotech companies through the turbulence of the past few years and the uncertainty of the next ones takes not just resilience, but an ability to grapple with the CEO’s paradox, according to Climb Bio CEO Aoife Brennan. This paradox requires preparing for repeated setbacks while planning optimistically, a duality that has been the story of biotech since the outbreak of the pandemic, said Brennan. In conversation with Editor in Chief Simone Fishburn on The BioCentury Show, Brennan discu...

    ٣٢ من الدقائق
  6. Ep. 72 - Outlook for Biotech M&A and Financing: Sidley's Robert Darwin

    ١٢‏/٠٥‏/١٤٤٦ هـ

    Ep. 72 - Outlook for Biotech M&A and Financing: Sidley's Robert Darwin

    With new governments both side of the pond, capital markets picking up, and some geopolitical overhang, there’s a mixed feast for biotech, with a net trend to the positive, says Sidley Austin’s Robert Darwin, who specializes in global M&A and private equity for life sciences and healthcare companies and investors. In conversation with Editor in Chief Simone Fishburn on The BioCentury Show, Darwin, who is based in London, discussed the consequences for biotech of the changing forces as we ...

    ٣٦ من الدقائق
  7. Ep. 71 - Pazdur Unplugged: FDA Director Richard Pazdur on the Past, Future of Cancer Treatments

    ٢٨‏/٠٤‏/١٤٤٦ هـ

    Ep. 71 - Pazdur Unplugged: FDA Director Richard Pazdur on the Past, Future of Cancer Treatments

    Richard Pazdur, director of FDA’s Oncology Center of Excellence, joined FDA in 1999. Looking back on his 25th anniversary, he draws a line between unpopular decisions at the start of his tenure and a surge in cancer drug development over the last 20 years. He believes this and other lessons from the regulation of oncology can be applied broadly across FDA. The BioCentury Show discussed these lessons, as well as Pazdur’s views about advisory committees, pragmatic trials, dose optimization and ...

    ٤٢ من الدقائق
  8. Ep. 70 - Trends in Global Biopharma Deals: Lazard’s Kingston and Raine

    ١٥‏/٠٤‏/١٤٤٦ هـ

    Ep. 70 - Trends in Global Biopharma Deals: Lazard’s Kingston and Raine

    With most of the highly attractive late-stage assets already scooped up, pharmas are turning their sights to Phase II companies, and lining up their case to make an attractive offer and move fast. About 40% of the M&A deals in 2023-24 were completed in less than six weeks, from approach to announcement, according to Lazard’s data. Michael Kingston and Dale Raine, global co-heads of biopharma at Lazard, joined The BioCentury Show this week to discuss the M&A outlook amid the still-prec...

    ٣٤ من الدقائق
مشاهدة الكل (٢٧)

التقييمات والمراجعات

٤٫٦
من ٥
‫١٠ من التقييمات‬

حول

Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine. Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues. The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine. Don't miss this event, every two weeks, now available as a video webcast or audio podcast.

المعلومات

  • قناة
    BioCentury Podcasts
  • صناع العمل
    BioCentury
  • سنوات النشاط
    ١٤٤٥ هـ - ١٤٤٦ هـ
  • الحلقات
    ٢٧
  • التقييم
    ملائم
  • حقوق النشر
    © 2025 BioCentury Inc. All Rights Reserved.
  • موقع البرنامج على الويب
    The BioCentury Show

المزيد من BioCentury Podcasts

قد يعجبك أيضًا

للاستماع إلى حلقات ذات محتوى فاضح، قم بتسجيل الدخول.

اطلع على آخر مستجدات هذا البرنامج

قم بتسجيل الدخول أو التسجيل لمتابعة البرامج وحفظ الحلقات والحصول على آخر التحديثات.
تحديد بلد أو منطقة

أفريقيا والشرق الأوسط، والهند

آسيا والمحيط الهادئ

أوروبا

أمريكا اللاتينية والكاريبي

الولايات المتحدة وكندا